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A B S T R A C T
Intravesical bacillus Calmette-Guérin (BCG) is widely used for high-risk, non-muscle-invasive bladder
cancer. This report describes four cases that illustrate the spectrum of BCG-induced complications,
varying from granulomatous prostatitis to sepsis. There is considerable debate regarding whether
inflammation or infection is the predominant mechanism in the pathogenesis of BCG disease. In two
patients with a systemic illness, the symptoms first resolved after adding prednisone, indicating a
principal role for inflammation in systemic disease. In vitro testing of T-cell responses and a
mycobacterial growth inhibition assay were performed for these patients with systemic disease. The
patient with mild symptoms showed more effective in vitro growth reduction of BCG, while the patient
with sepsis and organ involvement had high T-cell responses but ineffective killing. While these findings
are preliminary, it is believed that immunological assays, as described in this report, may provide a better
insight into the pathogenesis of BCG disease in individual patients, justifying further research.
© 2018 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Intravesical bacillus Calmette–Guérin (BCG) instillation follow-
ing transurethral resection (TUR) is considered the gold standard in
the treatment of high-risk, non-muscle-invasive bladder cancer.
Compared with the use of TUR alone, additional intravesical BCG
significantly reduces disease recurrence and the risk of progression* Corresponding author at: Department of Infectious Diseases, C5P-40, Leiden
University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).to invasive disease (Shelley et al., 2010). However, BCG-related
complications are common and may necessitate treatment discon-
tinuation. Side effects limited to the genitourinary tract include
chemical cystitis (35%), bacterial cystitis (23.3%), macroscopic
haematuria (22.6%), and symptomatic granulomatous prostatitis
(0.9%). Systemic complications are persistent high-grade fever as an
isolated manifestation (2.9%), pneumonitis with or without hepatitis
(0.7%), and sepsis (0.4%) (Brausi et al., 2014; Lamm et al., 1992). The
International Bladder Cancer Group recommends deferring BCG
instillation in the case of traumatic catheterization, concurrent
urinary tract infection, and TUR in the past 2 weeks, since these risk
factors may facilitate haematogenous dissemination (Witjes et al.,
2008). In a randomized controlled trial comparing one-third dose to
full-dose BCG for 1 or 3 years, the incidence of side effects did not
differ between the groups (Brausi et al., 2014).
It is unclear whether inflammation or infection underlies these
BCG-related complications, and their relative importance may vary
between patients. Since a diagnostic tool to make this distinction isciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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frequently initiated and anti-inflammatory drugs are added in the
case of systemic disease, with the risk of side effects.
This report describes four cases illustrating the spectrum of BCG
disease. In two patients with a systemic illness, immunological assays
including a novel mycobacterial growth inhibition assay (MGIA) were
performed, with the aim of studying the individual pathogenesis.
Case reports
The clinical characteristics of the patients are described in detail in
Table 1. In short, patient 1 was a 66-year-old man complaining ofTable 1





































































































































ALP (in U/l), alkaline phosphatase; ALT (in U/l), alanine aminotransferase; AST (in U/l), asp
pulmonary disease; CRP (in mg/l), C-reactive protein; CT, computed tomography; ESR
aneurysm repair; GGT (in U/l), gamma-glutamyltransferase; INH, isoniazid; KLH, keyhole
mg/l), prostate-specific antigen; RIF, rifampicin; TUR, transurethral resection.anejaculation, dysuria, and frequency at 1 month after the sixth BCG
instillation. A pelvic computed tomography (CT) scan showed prostate
abnormalities (Figure 1A), with chronic granulomatous inflammation
in a biopsy (Figure 2). The patient was treated with isoniazid and
rifampicin for 6 months, resulting in the resolution of symptoms.
Patient 2, a 70-year-old man, presented with weight loss,
malaise, and abdominal pain at 2 months after the 18th BCG
instillation. A CT scan revealed a leaking aneurysm of the
abdominal aorta, which was repaired via an endovascular
approach. Blood cultures were negative (no mycobacterial culture
was performed). After 10 months, a follow-up CT scan showed
progression of the aneurysm with leakage (Figure 1B) and and outcomes for four patients with BCG disease.
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Resolution of BCG disease
Intravesical KLH → recurrence
and death after 2 years
artate aminotransferase; BCG, bacillus Calmette–Guérin; COPD, chronic obstructive
 (in mm), erythrocyte sedimentation rate; ETH, ethambutol; EVAR, endovascular
 limpet hemocyanin; M, male; M. bovis, Mycobacterium bovis; ND, not done; PSA (in
Figure 1. (A) Pelvic CT scan (coronal plane) of patient 1, displaying an inhomogeneous, enlarged prostate (P) and asymmetry of the seminal vesicles with hyperdensity of the
right seminal vesicle (R) compared to the left seminal vesicle (L). (B) Transverse abdominal CT scan of patient 2 showing leakage of contrast fluid (arrow) outside the
endovascular aortic stent. (C) Abdominal CT scan (coronal plane) of patient 4 showing hepatomegaly (craniocaudal diameter 22 cm) and perihilar lymphadenopathy (white
arrow). (D) High-resolution thoracic CT scan (maximum intensity projection) of patient 4 demonstrating a bilateral miliary pattern with multiple sub-millimetre pulmonary
nodules.
Figure 2. Prostate biopsy of patient 1 showing prostatic glands surrounded by a
fibromuscular stroma and granulomatous inflammation with multiple giant cells
(arrow).
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resection of the infected tissue, para-aortic lymph nodes, and
the spleen. Histology showed chronic granulomatous inflamma-
tion, and PCR on the resected tissue was positive for Mycobacterium
bovis. However, before antibiotic treatment could be initiated the
patient died due to aortic rupture.Patient 3, a 67-year-old man who had been vaccinated with BCG
in the past, developed a persistent high-grade fever, weight loss,
and malaise at 4 days after his first BCG instillation. Pulmonary
involvement was ruled out and liver enzymes were within normal
limits. The fever persisted despite ciprofloxacin and only
disappeared after prednisone was started. The high fever recurred
after the second BCG instillation and BCG treatment was
discontinued. After a renewed TUR and intravesical keyhole
limpet hemocyanin (KLH) instillations for local tumour recurrence,
the patient has been recurrence-free for 2 years.
Patient 4, a 77-year-old-man, presented with a high-grade fever,
cough, and dyspnoea at 1 day after traumatic BCG instillation
following many uneventful previous instillations. A CTscan revealed
a miliary lung pattern, while elevated liver enzymes and hepato-
megaly indicated hepatic involvement (Figure 1C, D). Treatment
with isoniazid, rifampicin, and ethambutol was initiated, but his
symptoms first resolved after prednisone was added 2 weeks later.
The antibiotics were discontinued after 1 month due to serious
hepatotoxicity and were not reintroduced given the favourable
clinical course. KLH instillations were given for recurrence and a
nephroureterectomy was performed after tumour progression. The
patient died 2 years later from metastasized disease.
Immunological assays
Immunological assays were performed for patients 3 and 4 who
both had early onset systemic complications. The study protocol
(P07.048) allowing exploratory research of immune responses in
Figure 3. (A) Proliferation of T-lymphocytes in response to Mycobacterium tuberculosis purified protein derivative (PPD) or control. Lymphocyte proliferation is measured as
the count per minute (cpm; 3H-thymidine incorporation) for three different antigen (PPD) concentrations (mg/ml). Bars are medians with the standard deviation of three
measurements. For patient 3, t = 1 is day 25 after BCG instillation (before initiating prednisone) and t = 2 is day 109 (following the cessation of prednisone). For patient 4, t = 1 is
day 57 after BCG instillation after tapering of prednisone (dose 2.5 mg every other day), t = 2 is day 138 (no prednisone), and t = 3 is day 216 (no prednisone). (B) Levels of IFN-g
production by peripheral blood mononuclear cells in response to PPD or control medium; for time points, see the caption for Figure 3A. (C) Mycobacterial growth inhibition
assay (MGIA): the capacity to control BCG growth is represented as log(CFU), as calculated from the time to positivity of the culture. Patients 3 and 4 are compared to five
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Board of Leiden University Medical Centre, and written informed
consent was obtained from the patients.
The lymphocyte stimulation assay was performed as described
previously (Arend et al., 2000). In short, peripheral blood
mononuclear cells (PBMC) were incubated with Mycobacterium
tuberculosis purified protein derivative (PPD) (Statens Serum
Institut, Copenhagen, Denmark) at 37 C in a humidified CO2
incubator. After 6 days, the supernatants were harvested for
analysis by interferon-gamma (IFN-g) ELISA (U-CyTech, Utrecht,
The Netherlands), and 3H-thymidine was added for the last 18 h to
assess proliferation.
For the MGIA, PBMC (1 106) were incubated with 100 colony-
forming units (CFU) of BCG on a rotator at 37 C in a humidified
CO2 incubator. After 4 days, cultures were transferred to
Mycobacteria Growth Indicator Tubes (MGIT; Becton and Dick-
inson, Franklin Lakes, NJ, USA) and placed in a BACTEC incubator
until growth was detected (Tanner et al., 2016). The mechanism of
the control of BCG outgrowth has been published recently
(Joosten et al., 2018).
Test results for patient 3, who had a high-grade fever without
organ involvement, showed a moderate mycobacterial antigen-
specific T-cell response, but enhanced in vitro growth inhibition
of BCG compared to healthy controls. In contrast, the test results
for patient 4, who presented with sepsis and organ involvement,
were characterized by a higher mycobacterial antigen T-cell
response associated with a lack of in vitro growth inhibition of
BCG (Figure 3).
Discussion
The broad range of possible complications after intravesical
BCG instillation, illustrated by these four patient cases, has
been described previously (Perez-Jacoiste Asin et al., 2014).
They vary from focal disease limited to the genitourinary tract,
e.g., granulomatous prostatitis (patient 1), cystitis, or epidi-
dymo-orchitis, to focal disease outside the genitourinary tract,
e.g., arthritis, mycotic aneurysm (patient 2), or uveitis, to
systemic reaction without organ involvement (patient 3), and
finally to full-blown sepsis with pneumonitis and/or hepatitis
(patient 4).
In view of the discussion regarding the relative contribution of
inflammation and infection to the pathogenesis of BCG-related
complications, the finding that acid-fast staining, mycobacterial
culture, and PCR often remain negative (as found in three of the
four patients presented here), favours the inflammation hypoth-
esis (Perez-Jacoiste Asin et al., 2014). Interestingly, both of the
patients with systemic BCG disease did not respond to antibiotic
therapy and symptoms only resolved after adding prednisone. A
good outcome in patients with systemic disease treated
exclusively with corticosteroids has been reported previously
(LeMense and Strange, 1994). However, increased mortality was
seen after treatment with prednisone alone in a mouse model of
intraperitoneal BCG infection (Koukol et al., 1995), indicating that
antibiotic therapy should not be withheld if infection is the
predominant pathogenic mechanism. A randomized controlled
trial comparing intravesical BCG with and without isoniazid
prophylaxis around the time of instillations showed no difference
in the incidence of focal or systemic complications, further
supporting inflammation as an important pathogenic mechanism
(Vegt et al., 1997).healthy non-BCG vaccinated or M. tuberculosis-exposed, PPD-negative controls (for tim
corresponds with low log(CFU). MGIA were always performed in duplicate. For controls, e
shown as separate dots. The lines represent the median value.Intravesical BCG results in marked leukocyturia, the influx of
immune cells into the bladder wall, and the release of cytokines
in the urine, which is more pronounced in the case of previous
BCG exposure, reflecting recall immune activation (Redelman-
Sidi et al., 2014). On the other hand, ofloxacin given after
intravesical BCG significantly reduced the incidence of compli-
cations compared to placebo (Colombel et al., 2006). Together
with the microbiological identification of M. bovis in some cases,
predominantly with focal disease, this argues in favour of
infection.
In agreement with previous large case series studies (Gonzalez
et al., 2003; Perez-Jacoiste Asin et al., 2014), the interval between
the last instillation and onset of symptoms was shorter for
patients 3 and 4 with systemic complications than for patients 1
and 2 with focal disease. In the case series by Gonzalez et al.
(2003), a late presentation with mostly focal disease was
microbiologically confirmed in two-thirds of the patients,
compared to only one-third of the patients with early systemic
disease. This suggests that acute inflammatory mechanisms play
a relatively larger role in the development of systemic reactions,
whereas focal disease is mainly caused by infection-induced
chronic inflammation.
Immune tests showed that mycobacterial antigen-specific T-
cell responses were highest in patient 4, who presented with
sepsis and organ involvement. Intriguingly, the blood cells of this
patient had limited capacity for in vitro growth inhibition of BCG,
while patient 3, who had fever in the absence of organ
involvement, showed enhanced in vitro BCG growth inhibition.
While no conclusions can be drawn from only two cases, these
immunological assays might provide a clue about the pathogen-
esis of BCG complications in individual patients. High mycobac-
terial antigen-specific T-cell responses would point to systemic
inflammation as the predominant mechanism, in accordance
with the beneficial effect of steroids. In patients with low in vitro
growth inhibition of BCG, infection might be more important,
explaining why these patients benefit more from tuberculostatic
drugs, although the duration of such treatment is debatable, as
illustrated by patient 4.
A preliminary model for the mechanism of action of BCG in
bladder cancer has been proposed (Redelman-Sidi et al., 2014),
consisting of internalization of live BCG by malignant urothelial
cells followed by MHC-II up-regulation in infected bladder cancer
cells and the presentation of a BCG- and/or tumour-specific
antigen to T-cells. This leads to T-cell-mediated cytotoxicity
specific to malignant urothelial cells. Since the patient with
enhanced in vitro growth inhibition of BCG is now recurrence-free
while the patient with limited in vitro growth inhibition died due
to tumour progression, one could speculate that differences
between individuals in the handling of live BCG by immune cells
and perhaps also malignant urothelial cells might be related to this
observation. This warrants further research.
In conclusion, the complications of intravesical BCG are
manifold and the contribution of inflammation and infection
varies between patients. Immunological assays have potential to
provide insight into the pathogenesis of BCG disease. Future
studies should also explore immunological mechanisms involved
in tumour control following BCG instillations.
Financial support
None.e points, see the caption for Figure 3A). Effective in vitro growth inhibition of BCG
ach dot represents the mean of duplicate values. For patients 3 and 4, duplicates are
68 M.P. Bilsen et al. / International Journal of Infectious Diseases 72 (2018) 63–68Conflict of interest
RP has no conflicts of interest, including specific financial
interests, relevant to the submitted work. His financial activities
outside the submitted work include being on the advisory board of
Janssen Biologics BV and Amgen Europe BV, and providing guest
lectures for AstraZeneca Netherlands. TO has no conflicts of
interest, including specific financial interests, relevant to the
submitted work. His financial activities outside the submitted
work include being a member of the senior management team of
the TB Vaccine Initiative (TBVI; www.tbvi.eu), receiving many
external research grants (governmental, European Commission),
reimbursement for travel costs for attending meetings, and
holding two EU patents. All other authors report no conflicts of
interest.
References
Arend SM, Geluk A, van Meijgaarden KE, van Dissel JT, Theisen M, Andersen P, et al.
Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-
specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10
and to mixtures of synthetic peptides. Infect Immun 2000;68:3314–21.
Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects
of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-
risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-
urinary cancers group randomised phase 3 study comparing one-third dose
with full dose and 1 year with 3 years of maintenance BCG. Eur Urol
2014;65:69–76.
Colombel M, Saint D, Chopin B, Nicolas L, Rischmann P. The effect of ofloxacin on
bacillus calmette-guerin induced toxicity in patients with superficial bladdercancer: results of a randomized, prospective, double-blind, placebo controlled,
multicenter study. J Urol 2006;176:935–9.
Gonzalez OY, Musher DM, Brar I, Furgeson S, Boktour MR, Septimus EJ, et al.
Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG
immunotherapy. Clin Infect Dis 2003;36:140–8.
Joosten SA, van Meijgaarden KE, Arend SM, Prins C, Oftung F, Korsvold GE, et al.
Mycobacterial growth inhibition is associated with trained innate immunity. J
Clin Invest 2018;128:1837–51.
Koukol SC, DeHaven JI, Riggs DR, Lamm DL. Drug therapy of bacillus Calmette-
Guerin sepsis. Urol Res 1995;22:373–6.
Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al.
Incidence and treatment of complications of bacillus Calmette-Guerin intra-
vesical therapy in superficial bladder cancer. J Urol 1992;147:596–600.
LeMense GP, Strange C. Granulomatous pneumonitis following intravesical BCG.
What therapy is needed?. Chest 1994;106:1624–6.
Perez-Jacoiste Asin MA, Fernandez-Ruiz M, Lopez-Medrano F, Lumbreras C, Tejido
A, San Juan R, et al. Bacillus Calmette-Guerin (BCG) infection following
intravesical BCG administration as adjunctive therapy for bladder cancer:
incidence, risk factors, and outcome in a single-institution series and review of
the literature. Medicine (Baltimore) 2014;93:236–54.
Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG
therapy for bladder cancer–a current perspective. Nat Rev Urol 2014;11:153–62.
Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder
cancer: a systematic review of randomised trials and meta-analyses. Cancer
Treat Rev 2010;36:195–205.
Tanner R, O’Shea MK, Fletcher HA, McShane H. In vitro mycobacterial growth
inhibition assays: a tool for the assessment of protective immunity and
evaluation of tuberculosis vaccine efficacy. Vaccine 2016;34:4656–65.
Vegt PD, van der Meijden AP, Sylvester R, Brausi M, Holtl W, de Balincourt C. Does
isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in
superficial bladder cancer? Interim results of European Organization for
Research and Treatment of Cancer Protocol 30911. J Urol 1997;157:1246–9.
Witjes JA, Palou J, Soloway M, Lamm D, Brausi M, Spermon JR, et al. Clinical practice
recommendations for the prevention and management of intravesical therapy-
associated adverse events. Eur Urol Suppl 2008;7:667–74.
